NCT02648282 2026-03-13
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
Clinical Trials
15 trialsNCT01088789 2025-08-26
Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03161379 2025-02-03
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03153410 2025-01-09
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT03329248 2024-12-12
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03006302 2024-10-08
Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03586869 2024-08-27
QUILT-3.080: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03190265 2024-08-07
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03136406 2024-06-11
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03387098 2024-05-22
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT00727441 2020-02-25
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00305760 2020-02-19
Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01362790 2019-06-06
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01417000 2018-05-08
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
Aduro Biotech, Inc.
Phase 2 Completed